Neogen Corp

Neogen Corp(NEOG)の株式分析

$11.810

-0.443 (-3.75%)終値時点

Loading chart…
高値
12.450
始値
12.270
出来高加重平均価格
11.98
出来高
2.46M
時価総額
3.46B
安値
11.680
売買代金
29.46M
EV/EBITDA(TTM)
29.40

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.

www.neogen.com

AI分析 of Neogen Corp (NEOG)

買い

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, and a significant improvement in financial performance, including a net loss reduction to $11.3 million in Q4 from a $612.2 million loss last year. Additionally, the stock has shown a year-to-date increase of 69.29%, indicating strong momentum. However, the main risk is the recent FDA warning that caused a 7.22% drop in shares, highlighting product safety concerns.

アナリスト評価(7)

-30.82% 下落余地
中立
0 買い
7 中立
0 売り
現在: 11.81
安値
6.50
平均
8.17
高値
10.00

Guggenheim

2026-09-30

目標株価

$14

買い

Guggenheim

2026-09-29

目標株価

$12

買い

Piper Sandler

2026-08-26

目標株価

$14

オーバーウェイト

Piper Sandler

2026-08-03

目標株価

$13

中立

Guggenheim

2026-01-09

目標株価

$12

買い

バリュエーション指標

Neogen Corp(NEOG)の現在の予想PERは16.00で、5年平均は31.44です。

予想PER

適正
5年平均 P/E
31.44
現在のP/E
16.00
割高
47.00
割安
15.88

予想EV/EBITDA

割高
5年平均 EV/EBITDA
16.73
現在のEV/EBITDA
29.40
割高
25.26
割安
8.20

予想PSR

適正
5年平均 P/S
3.61
現在のP/S
3.03
割高
5.33
割安
1.89

Alphio AI による NEOG の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%NEOG

$7.55

シナリオ価格

基

基本

基本 · 50%NEOG

$6.69

シナリオ価格

弱

弱気

弱気 · 25%NEOG

$6.11

シナリオ価格

NEOG を保有するクジラ

G

Gates Capital Management, Inc.

+ を保有NEOG

-7.42%

3か月リターン

イベントタイムライン

2026-10-07 (ET)

16:30:00

Major Averages Decline After Fed Meeting Minutes Release

12:30:00

Major Averages Broadly Lower as 10-Year Treasury Yield Rises to 5.356%

09:00:00

Stock Futures Point to Lower Open as Tech Stocks Weigh

2026-10-06 (ET)

20:00:00

Nasdaq and S&P 500 Hit Record Highs

16:30:00

Neogen Reports Q1 Revenue of $222.8M, Beating Expectations

ニュース

NEOG のよくある質問 — Alphio AI が回答

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, and a significant improvement in financial performance, including a net loss reduction to $11.3 million in Q4 from a $612.2 million loss last year. Additionally, the stock has shown a year-to-date increase of 69.29%, indicating strong momentum. However, the main risk is the recent FDA warning that caused a 7.22% drop in shares, highlighting product safety concerns.

7 analysts cover NEOG: 0 rate it Buy, 7 Hold and 0 Sell. The average price target is 8.17.

コミュニティ

もっと見る ↗
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める